You have free access to this content

Cancer

Cover image for Cancer

15 February 2010

Volume 116, Issue 4

Pages 777–1009

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Other Canary-funded research topics (page 778)

      Carrie Printz

      Version of Record online: 2 FEB 2010 | DOI: 10.1002/cncr.24978

    3. You have free access to this content
      Breast cancer rate continues to decline (page 779)

      Carrie Printz

      Version of Record online: 2 FEB 2010 | DOI: 10.1002/cncr.24979

    4. You have free access to this content
      Hispanics have a unique cancer risk profile (page 779)

      Carrie Printz

      Version of Record online: 2 FEB 2010 | DOI: 10.1002/cncr.24980

  2. Review Article

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      p53 and MDM2 in renal cell carcinoma : Biomarkers for disease progression and future therapeutic targets? (pages 780–790)

      Aidan P. Noon, Nikolina Vlatković, Radosław Polański, Maria Maguire, Howida Shawki, Keith Parsons and Mark T. Boyd

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24841

      • original image
      • original image

      A body of evidence exists to suggest p53 immunohistochemical staining of renal cell carcinoma identifies poor prognosis patients. The p53/MDM2 pathway may hold the key to improving survival for patients with renal cell carcinoma.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer (pages 791–798)

      Mary E. Abusief, Stacey A. Missmer, Elizabeth S. Ginsburg, Jane C. Weeks and Ann H. Partridge

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24835

      In this retrospective review of data from premenopausal women who were treated for early breast cancer, the authors evaluated rates of amenorrhea after treatment with either doxorubicin and cyclophosphamide (AC) or AC with paclitaxel (AC-T) given either every 3 weeks, or as a dose-dense (DD) regimen, or after treatment with AC followed either by weekly T plus trastuzumab or by trastuzumab. These newer regimens, which are used increasingly in the adjuvant treatment of women with early breast cancer, did not appear to increase the risk of amenorrhea in premenopausal women.

    2. You have free access to this content
      Ovarian metastases from breast cancer : Report of 29 cases (pages 799–804)

      Veronique Bigorie, Philippe Morice, Pierre Duvillard, Martine Antoine, Annie Cortez, Jean François Flejou, Serge Uzan, Emile Darai and Emmanuel Barranger

      Version of Record online: 29 DEC 2009 | DOI: 10.1002/cncr.24807

      • original image
      • original image

      Breast cancers may be associated with ovarian metastases. The current results indicated that surgical resection tends to increase survival.

    3. You have free access to this content
      Early 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy (pages 805–813)

      Andrea A. Martoni, Claudio Zamagni, Sara Quercia, Marta Rosati, Nicoletta Cacciari, Alessandra Bernardi, Alessandra Musto, Stefano Fanti, Donatella Santini and Mario Taffurelli

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24820

      • original image
      • original image

      Early evaluation of metabolic response by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography during preoperative chemotherapy for breast cancer was able to identify 30% of patients who would not obtain an optimal pathologic response at surgery after completion of chemotherapy program. All of these patients had estrogen receptor-positive tumors. This information could be used in the decision-making process.

    4. You have free access to this content
      A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer (pages 814–821)

      Stacy L. Moulder, Frankie A. Holmes, Anthony W. Tolcher, Peter Thall, Kristine Broglio, Vicente Valero, Aman U. Buzdar, Susan G. Arbuck, Andrew Seidman and Gabriel N. Hortobagyi

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24870

      • original image

      Paclitaxel administered by 96-hour infusion every 3 weeks did not significantly improve response or time to disease progression compared with 3-hour infusion for the treatment of metastatic breast cancer. The 96-hour infusion was more cumbersome to administer and was associated with greater myelosuppression (but less neuropathy and myalgia) compared with the 3-hour schedule.

    5. Gastrointestinal Disease
      You have free access to this content
      Long-term quality of life after radiotherapy for the treatment of anal cancer (pages 822–829)

      Prajnan Das, Scott B. Cantor, Crystal L. Parker, Joan B. Zampieri, Andrew Baschnagel, Cathy Eng, Marc E. Delclos, Sunil Krishnan, Nora A. Janjan and Christopher H. Crane

      Version of Record online: 29 DEC 2009 | DOI: 10.1002/cncr.24906

      The current study evaluated long-term quality of life (QoL) in patients treated with radiotherapy for anal cancer, using the Functional Assessment of Cancer Therapy-Colorectal and the Medical Outcomes Study Sexual Problems Scale instruments. Patients reported acceptable overall QoL scores, but poor sexual function scores.

    6. You have free access to this content
      Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer : A prospective randomized controlled study (pages 830–836)

      Marjolein J. M. Morak, Chulja J. Pek, Erwin J. O. Kompanje, Wim C. J. Hop, Geert Kazemier and Casper H. J. van Eijck

      Version of Record online: 22 DEC 2009 | DOI: 10.1002/cncr.24809

      • original image
      • original image
      • original image
      • original image
      • original image

      Adjuvant celiac axis infusion chemotherapy combined with radiotherapy improved quality of life compared with observation alone in patients with resected pancreatic and periampullary cancers. Impairment in quality of life during or after treatment is no longer a reason to deny patients adjuvant therapies.

    7. Genitourinary Disease
      You have free access to this content
      Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy (pages 837–842)

      Amy M. Dosoretz, Ming-Hui Chen, Sharon A. Salenius, Rudolf H. Ross, Daniel E. Dosoretz, Michael J. Katin, Constantine Mantz, Bruce M. Nakfoor and Anthony V. D'Amico

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24750

      • original image
      • original image

      The current results indicated that men aged ≥73 years with localized prostate cancer who receive brachytherapy and neoadjuvant hormone therapy (NHT) may have an increased risk of all-cause mortality compared with men who do not receive NHT. The authors concluded that it is important to weigh the risks and benefits of NHT when designing a treatment plan for patients with prostate cancer.

    8. Gynecologic Oncology
      You have free access to this content
      Serum amyloid A : A novel biomarker for endometrial cancer (pages 843–851)

      Emiliano Cocco, Stefania Bellone, Karim El-Sahwi, Marilisa Cargnelutti, Natalia Buza, Fattaneh A. Tavassoli, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli and Alessandro D. Santin

      Version of Record online: 29 DEC 2009 | DOI: 10.1002/cncr.24838

      • original image
      • original image
      • original image

      Serum amyloid A (SAA) is an acute phase protein recently reported as a potentially useful biomarker for some human tumors. The authors report evidence that SAA is not only a liver-secreted protein, but is also an endometrial endometrioid carcinoma cell product. SAA is highly expressed and actively secreted by endometrial endometrioid carcinoma, and it is present in high concentration in the serum of endometrial endometrioid carcinoma patients. SAA may represent a novel biomarker for endometrial endometrioid carcinoma to assist in staging patients preoperatively, and to monitor early disease recurrence and response to therapy.

    9. Hematologic Malignancies
      You have free access to this content
      Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma (pages 852–862)

      Michael R. Bishop, Robert M. Dean, Seth M. Steinberg, Jeanne Odom, Seth M. Pollack, Steven Z. Pavletic, Claude Sportes, Ronald E. Gress and Daniel H. Fowler

      Version of Record online: 29 DEC 2009 | DOI: 10.1002/cncr.24845

      • original image
      • original image
      • original image
      • original image

      The specific disease response obtained with salvage chemotherapy for relapsed and refractory non-Hodgkin lymphoma correlates with post-transplant outcomes in patients being considered for reduced-intensity allogeneic stem cell transplantation. The differentiation of chemotherapy sensitivity, based on specific responses to salvage chemotherapy, identifies specific patient populations that may or may not benefit from this procedure.

    10. You have free access to this content
      Primary central nervous system post-transplantation lymphoproliferative disorder : An International Primary Central Nervous System Lymphoma Collaborative Group Report (pages 863–870)

      Robert Cavaliere, Gina Petroni, Maria B. Lopes and David Schiff

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24834

      • original image

      Primary central nervous system post-transplantation lymphoproliferative disorder, typically an Epstein-Barr virus-induced B-cell lymphoma, is an uncommon complication of solid organ transplantation. After pathologic confirmation, an aggressive approach, including radiotherapy, chemotherapy, and rituximab, should be considered in certain patients, because prolonged remission is possible.

    11. You have free access to this content
      Primary lymphoma of bone in adult patients (pages 871–879)

      Muhammad U. Jawad, Michaela M. Schneiderbauer, Elijah S. Min, Michael C. Cheung, Leonidas G. Koniaris and Sean P. Scully

      Version of Record online: 30 DEC 2009 | DOI: 10.1002/cncr.24828

      • original image
      • original image
      • original image
      • original image
      • original image

      In this study, 1500 adult patients with primary lymphoma of bone had 5-year and 10-year survival rates of 58% and 45%, respectively. An improved prognosis was associated with a single bone lesion and younger patient age. These variables were identified as independent prognostic factors and indicated that this subgroup of patients may be amenable to more focused treatment.

    12. You have free access to this content
      Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia (pages 880–887)

      Jeffrey J. Tarrand, Michael J. Keating, Apostolia M. Tsimberidou, Susan O'Brien, Rocco P. LaSala, Xiang-Yang Han and Carlos E. Bueso-Ramos

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24839

      • original image

      Detection of Epstein-Barr virus latent membrane protein 1 (LMP1) transcription indicates an activated viral state and is associated with cell proliferation and arrest of normal apoptotic responses. The authors demonstrated LMP1 in 14% of a consecutive sample of chronic lymphocytic leukemia (CLL) patients and in association with a quantitatively increased CLL burden on bone marrow histopathology.

    13. Lung Disease
      You have free access to this content
      Should extrapulmonary small cell cancer be managed like small cell lung cancer? (pages 888–895)

      Sinead M. Brennan, Deborah L. Gregory, Alison Stillie, Alan Herschtal, Michael Mac Manus and David L. Ball

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24858

      • original image
      • original image
      • original image

      The objective of the current study was to determine whether it was reasonable to apply management strategies designed for small cell lung cancer (SCLC) to patients with extrapulmonary small cell carcinoma. Although prophylactic cranial irradiation (PCI) was associated with improved overall survival, brain metastasis was less frequent than in SCLC and, therefore, the potential benefit of PCI was less than in SCLC.

    14. You have free access to this content
      Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk (pages 896–902)

      Yugo Tanaka, Yoshimasa Maniwa, Vladimir P. Bermudez, Takefumi Doi, Wataru Nishio, Chiho Ohbayashi, Yutaka Okita, Jerard Hurwitz, Yoshitake Hayashi and Masahiro Yoshimura

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24850

      Analysis of the presence of XRCC1 194Trp homozygote, POLδ1 119His homozygote, and RAD9 239Arg heterozygote variants revealed that their coassociation leads to a significant risk for the development of lung adenocarcinoma. Inclusive analyses of different single nucleotide polymorphisms were important in this cancer risk study.

    15. Discipline

      Diagnostic Imaging
      You have free access to this content
      Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer (pages 903–912)

      Nina A. Mayr, William T. C. Yuh, David Jajoura, Jian Z. Wang, Simon S. Lo, Joseph F. Montebello, Kyle Porter, Dongqing Zhang, D. Scott McMeekin and John M. Buatti

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24822

      • original image
      • original image

      Functional magnetic resonance imaging (MRI) parameters quantifying heterogeneous tumor perfusion and subtle tumor volume change early during radiation/chemotherapy of cervical cancer are independent predictors of tumor recurrence and death in cervical cancer. The combined prediction by both classic clinical prognostic factors and functional MRI can be used as a novel ultra-early predictive assay for ultimate therapy outcome, and may serve to personalize therapy strategies in cervical cancer.

    16. Disparities Research
      You have free access to this content
      Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers (pages 913–921)

      Tracy A. Battaglia, M. Christina Santana, Sharon Bak, Manjusha Gokhale, Timothy L. Lash, Arlene S. Ash, Richard Kalish, Stephen Tringale, James O. Taylor and Karen M. Freund

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24851

      Among a group of racially/ethnically diverse women seeking care at 6 urban community health centers, we sought to measure time and identify predictors of timely follow-up after breast and cervical cancer screening abnormalities. Site of care, rather than any sociodemographic characteristic of individuals, including race/ethnicity, was the only significant predictor of delay in both groups.

    17. You have free access to this content
      A trial of 3 interventions to promote colorectal cancer screening in African Americans (pages 922–929)

      Daniel S. Blumenthal, Selina A. Smith, Charlye D. Majett and Ernest Alema-Mensah

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24842

      • original image

      In this community intervention trial, the authors tested 3 interventions to promote colorectal cancer screening among African Americans: reduced out-of-pocket expense, one-on-one education, and group education. The Group Education intervention was the most efficacious of the 3 interventions.

    18. You have free access to this content
      Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer : A 2-Step Process (pages 930–939)

      Taylor S. Riall, Courtney M. Townsend Jr., Yong-Fang Kuo, Jean L. Freeman and James S. Goodwin

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24836

      • original image

      Black patients with locoregional pancreatic cancer were 43% less likely than white patients to undergo surgical evaluation and were 36% less likely to undergo surgery even after they were evaluated by a surgeon. Achieving higher rates of surgical evaluation in black patients would be the first step to eliminating the observed disparity in surgical resection rates and long-term survival.

    19. Epidemiology
      You have free access to this content
      Generational risks for cancers not related to tobacco, screening, or treatment in the United States (pages 940–948)

      Yueh-Ying Han, Devra L. Davis, Joel L. Weissfeld and Gregg E. Dinse

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24747

      • original image

      Cancers with no known relation to smoking or screening have increased throughout the past 3 decades. These trends are important indicators of future demand for healthcare and also suggest the need to explore novel risk factors for cancer that could be targets for preventive policies.

    20. You have free access to this content
      Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004 (pages 949–956)

      Sophia S. Wang, J. Daniel Carreon, Scarlett L. Gomez and Susan S. Devesa

      Version of Record online: 22 DEC 2009 | DOI: 10.1002/cncr.24843

      • original image
      • original image

      There exists large variation in invasive cervical cancer incidence patterns among Asian ethnic groups in the United States and in comparison with rates for blacks, Hispanics, and whites. Early detection and prevention strategies for cervical cancer among Asians require targeted strategies by ethnic group.

    21. Medical Oncology
      You have free access to this content
      Impact of smoking on patients with stage III colon cancer : Results from Cancer and Leukemia Group B 89803 (pages 957–966)

      Nadine Jackson McCleary, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al Benson, Richard Goldberg and Jeffrey A. Meyerhardt

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24866

      • original image
      • original image

      Data on smoking history were captured for 1045 subjects with stage III colon cancer (46% never smokers; 44% past; 10% current). Total tobacco usage early in life may influence outcomes in patients with stage III colon cancer.

    22. Outcomes Research
      You have free access to this content
      Perils of quinolone exposure in cancer patients : Breakthrough bacteremia with multidrug-resistant organisms (pages 967–973)

      Gopi Rangaraj, Bruno P. Granwehr, Ying Jiang, Ray Hachem and Issam Raad

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24812

      In the current study, the authors examined the impact of antibiotics on the emergence of multidrug-resistant (MDR) breakthrough bacteremia in cancer patients. The isolation of MDR bacteria was strongly associated with the use of fluoroquinolones.

    23. Pediatric Oncology
      You have free access to this content
      Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors : A report from the Childhood Cancer Survivor Study (pages 974–982)

      Meagan Lansdale, Sharon Castellino, Neyssa Marina, Pamela Goodman, Melissa M. Hudson, Ann C. Mertens, Stephanie M. Smith, Wendy Leisenring, Leslie L. Robison and Kevin C. Oeffinger

      Version of Record online: 29 DEC 2009 | DOI: 10.1002/cncr.24810

      Pediatric cancer survivors who are at risk of transfusion-acquired hepatitis C virus (HCV) infection after cancer therapy before routine blood donor screening lack knowledge of HCV testing and blood transfusion history. Among >9000 participants in the Childhood Cancer Survivor Study with an elevated risk of HCV, <30% reported a prior test for HCV, and 50% recalled a treatment-related blood transfusion.

    24. You have free access to this content
      Ethnic and racial differences in patients with Ewing sarcoma (pages 983–988)

      Jennifer Worch, Katherine K. Matthay, John Neuhaus, Robert Goldsby and Steven G. DuBois

      Version of Record online: 5 JAN 2010 | DOI: 10.1002/cncr.24865

      • original image

      Patient and tumor characteristics in Ewing sarcoma differ by race and ethnicity. Overall survival also was found to differ by race and ethnicity, even after controlling for known prognostic factors.

    25. Symptom Control and Palliative Care
      You have free access to this content
      Percutaneous radiofrequency ablation of painful osseous metastases : A multicenter American College of Radiology Imaging Network trial (pages 989–997)

      Damian E. Dupuy, Dawei Liu, Donna Hartfeil, Lucy Hanna, Jeffrey D. Blume, Kamran Ahrar, Robert Lopez, Howard Safran and Thomas DiPetrillo

      Version of Record online: 29 DEC 2009 | DOI: 10.1002/cncr.24837

      • original image
      • original image

      Percutaneous radiofrequency ablation was used to treat painful osseous metastases under computed tomography guidance. This cooperative group trial showed technical safety and statistically significant improvements in pain measures.

    26. You have free access to this content
      Physician factors associated with discussions about end-of-life care (pages 998–1006)

      Nancy L. Keating, Mary Beth Landrum, Selwyn O. Rogers Jr, Susan K. Baum, Beth A. Virnig, Haiden A. Huskamp, Craig C. Earle and Katherine L. Kahn

      Version of Record online: 11 JAN 2010 | DOI: 10.1002/cncr.24761

      • original image

      In a national survey of physicians caring for cancer patients, most physicians reported they would not discuss end-of-life options with terminally ill patients who are feeling well, and instead would wait for symptoms or until there are no more treatments to offer. Additional research is needed to understand physicians' reasons for timing of discussions and how their propensity to aggressively treat metastatic disease influences timing, as well as how the timing of discussions influences patient and family experiences at the end of life.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content

SEARCH

SEARCH BY CITATION